Savara's rare lung disease therapy meets main goal in late-stage study
Send a link to a friend
[June 26, 2024]
(Reuters) -Savara said on Wednesday its experimental therapy met
the main goal of a late-stage trial by improving a measure of lung
function in patients with a rare disease that causes breathing
difficulties, sending its shares up 31%.
The therapy is being developed to treat patients with autoimmune
pulmonary alveolar proteinosis (aPAP), which can lead to shortness of
breath, cause scarring in the lungs and even lead to a need for a lung
transplant.
The disease is estimated to affect less than 5,000 people in the United
States, according to government data.
Savara's inhaled therapy, molgramostim, helped improve a measure of lung
capacity that tracks the ability of the lungs to transfer gas from
inhaled air to red blood cells in blood capillaries in the lung,
compared with a placebo.
[to top of second column]
|
![](http://archives.lincolndailynews.com/2024/Jun/26/images/ads/current/graue_lda_TUBBAKER_062524.png) Molgramostim was well-tolerated and
the frequency of adverse events was generally similar between
treatment groups, the drug developer said.
Savara plans to submit a marketing application for the therapy in
the first half of 2025.
(Reporting by Pratik Jain in Bengaluru; Editing by Tasim Zahid and
Devika Syamnath)
[© 2024 Thomson Reuters. All rights reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |